GenSight appoints big pharma vets to management team ahead of Lumevoq launch

French biotech GenSight Biologics (Euronext: SIGHT), which is developing gene therapy for rare and neurodegenerative diseases of the eye, is adding to its management team in anticipation of the European commercialization of Lumevoq (lenadogene nolparvovec).

The drug is GenSight’s lead therapy in development but has suffered regulatory setbacks on both sides of the Atlantic and, according to the company’s last comment, European approval is now expected in the third quarter of 2023.

Philippe Motté has been named senior vice president, regulatory and quality reporting to chief executive Bernard Gilly and a member of the executive committee. Mr Motté will be responsible for ensuring consistency of activities in relation to regional and local regulatory authorities, coordinating teams to prepare for pre-marketing inspections of Lumevoq and ensuring regulatory compliance in the future marketing of the drug. He worked for many years in regulatory, quality and commercial roles in leading healthcare companies such as Sanofi (then as Pasteur-Mérieux), GSK (then as SmithKline-Beecham), Roche, Ipsen, Abbvie and Medday Pharmaceuticals.